Plasma endothelin-1 and vascular endothelial growth factor levels and their relationship to hemodynamics in idiopathic pulmonary fibrosis

Respiration

Volumn 84, Issue 4, 2012, Pages 299-305

  Ventetuolo, Corey E ^a   Kawut, Steven M ^b   Lederer, David J ^c,d  

^a Department of Medicine ^*  (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Columbia University ^*  (United States)

Author keywords

Biomarkers; Endothelin 1; Idiopathic pulmonary fibrosis; Pulmonary hypertension; Vascular endothelial growth factor

Indexed keywords

ENDOTHELIN 1; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; FIBROSING ALVEOLITIS; HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

AGED; ARTERIAL PRESSURE; CROSS-SECTIONAL STUDIES; ENDOTHELIN-1; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY ARTERY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR RESISTANCE;

EID: 84867035466     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000339105     Document Type: Article

References (46)

1. Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD: Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007; 30: 715-721.
2. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF: Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746-752.
3. Nathan SD, Noble PW, Tuder RM: Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med 2007; 175: 875-880.
4. Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, Ryu JH: Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 2393-2399.
5. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD: Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007; 131: 657-663.
6. Patel NM, Lederer DJ, Borczuk AC, Kawut SM: Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007; 132: 998-1006.
7. Pitsiou G, Papakosta D, Bouros D: Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Respiration 2011; 82: 294-304.
8. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
9. Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matsumura M, Ueda T, Temma S, Shirakami G, Imura H, Mikawa H: Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation 1991; 84: 2280-2285.
10. Dupuis J, Stewart DJ, Cernacek P, Gosselin G: Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996; 94: 1578-1584.
11. Montani D, Souza R, Binkert C, Fischli W, Simonneau G, Clozel M, Humbert M: Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. Chest 2007; 131: 101-108.
12. Stewart DJ, Levy RD, Cernacek P, Langleben D: Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114: 464-469.
13. Carratu P, Scoditti C, Maniscalco M, Seccia TM, Di Gioia G, Gadaleta F, Cardone RA, Dragonieri S, Pierucci P, Spanevello A, Resta O: Exhaled and arterial levels of endothelin-are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension. BMC Pulm Med 2008; 8: 20.
14. Hiramoto Y, Shioyama W, Higuchi K, Arita Y, Kuroda T, Sakata Y, Nakaoka Y, Fujio Y, Yamauchi-Takihara K: Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension. J Cardiol 2009; 53: 374-380.
15. Hiramoto Y, Shioyama W, Kuroda T, Masaki M, Sugiyama S, Okamoto K, Hirota H, Fujio Y, Hori M, Yamauchi-Takihara K: Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension. Circ J 2007; 71: 367-369.
16. Jain R, Shaul PW, Borok Z, Willis BC: Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-1. Am J Respir Cell Mol Biol 2007; 37: 38-47.
17. Giaid A, Michel RP, Stewart DJ, Sheppard M, Hamid Q, Corrin B: Expression of endothelin-1 in lungs of patients with crypogenic fibrosing alveolitis. Lancet 1993; 341: 1550-1554.
18. Saleh D, Furukawa K, Tsao M, Maghazachi A, Corrin B, Yanagisawa M, Barnes P, Giaid A: Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997; 16: 187-193.
19. Hocher B, Schwarz A, Fagan KA, Thone-Reineke C, El-Hag K, Kusserow H, Elitok S, Bauer C, Neumayer H-H, Rodman DM, Theuring F: Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 2000; 23: 19-26.
20. Park S-H, Saleh D, Giaid A, Michel RP: Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997; 156: 600-608.
21. Ross B, D'Orléans-Juste P, Giaid A: Potential role of endothelin-1 in pulmonary fibrosis: from the bench to the clinic. Am J Respir Cell Mol Biol 2010; 42: 16-20.
22. Shi-wen X, Kennedy L, Renzoni EA, Bou-Gharios G, Bois RMd, Black CM, Denton CP, Abraham DJ, Leask A: Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheumat 2007; 56: 4189-4194.
23. Shi-Wen X, Rodriguez-Pascual F, Lamas S, Holmes A, Howat S, Pearson JD, Dashwood MR, du Bois RM, Denton CP, Black CM, Abraham DJ, Leask A: Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol 2006; 26: 5518-5527.
24. Uguccioni M, Pulsatelli L, Grigolo B, Facchini A, Fasano L, Cinti C, Fabbri M, Gasbarrini G, Meliconi R: Endothelin-1 in idiopathic pulmonary fibrosis. J Clin Pathol 1995; 48: 330-334.
25. Trakada G, Spiropoulos K: Arterial endothelin-1 in interstitial lung disease patients with pulmonary hypertension. Monaldi Arch Chest Dis 2001; 56: 379-383.
26. Simler NR, Brenchley PE, Horrocks AW, Greaves SM, Hasleton PS, Egan JJ: Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 2004; 59: 581-585.
27. Tuder R, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, Cool C, Bishop A, Geraci M, Semenza G: Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 2001; 195: 367-374.
28. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, Tuder RM: Threedimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers: evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999; 155: 411-419.
29. Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M, Sasano H, Kondo T, Nukiwa T: Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 169: 1203-1208.
30. Hamada N, Kuwano K, Yamada M, Hagimoto N, Hiasa K, Egashira K, Nakashima N, Maeyama T, Yoshimi M, Nakanishi Y: Antivascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol 2005; 175: 1224-1231.
31. Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, Schnapp A, Park JE: Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007; 29: 976-985.
32. Farkas L, Farkas D, Ask K, Moller A, Gauldie J, Margetts P, Inman M, Kolb M: VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J Clin Invest 2009; 119: 1298-1311.
33. Ando M, Miyazaki E, Ito T, Hiroshige S, Nureki S, Ueno T, Takenaka R, Fukami T, Kumamoto T: Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis. Lung 2010; 188: 247-252.
34. American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000; 161: 646-664.
35. ATS Statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
36. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson D, MacIntyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G: Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26: 511-522.
37. Yamakami T, Taguchi O, Gabazza E, Yoshida M, Kobayashi T, Kobayashi H, Yasui H, Ibata H, Adachi Y: Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease. Relation with pulmonary hypertension during exercise. Eur Respir J 1997; 10: 2055-2060.
38. Trakada G, Nikolaou E, Pouli A, Tsiamita M, Spiropoulos K: Endothelin-1 levels in interstitial lung disease patients during sleep. Sleep Breath 2003; 7: 111-118.
39. Maeder MT, Brutsche MH, Arenja N, Socrates T, Reiter M, Meissner J, Staub D, Morgenthaler NG, Bergmann A, Mueller C: Biomarkers and peak oxygen uptake in patients with chronic lung disease. Respiration 2010; 80: 543-552.
40. Kim KK, Chapman HA: Endothelin-1 as initiator of epithelial-mesenchymal transition: potential new role for endothelin-1 during pulmonary fibrosis. Am J Respir Cell Mol Biol 2007; 37: 1-2.
41. Haynes WG, Webb DJ: The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci (Lond) 1993; 84: 485-500.
42. King J, Talmadge E, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J: BUILD-3:a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 92-99.
43. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stahler G, Leconte I, Roux S, Raghu G: BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81.
44. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier J-F, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ, on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis: An Official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
45. Tian J, Smith A, Nechtman J, Podolsky R, Aggarwal S, Snead C, Kumar S, Elgaish M, Oishi P, Goerlach A, Fratz S, Hess J, Catravas JD, Verin AD, Fineman JR, She J-X, Black SM: Effect of PPAR inhibition on pulmonary endothelial cell gene expression: gene profiling in pulmonary hypertension. Physiol Genomics 2009; 40: 48-60.
46. Cho YJ, Han JY, Lee SG, Jeon BT, Choi WS, Hwang YS, Roh GS, Lee JD: Temporal changes of angiopoietins and Tie2 expression in rat lungs after monocrotaline-induced pulmonary hypertension. Comp Med 2009; 59: 350-356.